# COVID-19 Antibody Responses In Cystic Fibrosis

> **NCT05074680** · — · ACTIVE_NOT_RECRUITING · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 5 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DIAGNOSTIC_TEST:** Blood sampling

## Key facts

- **NCT ID:** NCT05074680
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-14
- **Primary completion:** 2023-12-31
- **Final completion:** 2025-07-31
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2024-10-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05074680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05074680, "COVID-19 Antibody Responses In Cystic Fibrosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05074680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*